Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3 publications
Correction to "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma".
Journal: ACS medicinal chemistry letters
Published: September 27, 2017
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.
Journal: ACS medicinal chemistry letters
Published: April 05, 2017
Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases.
Journal: Bioorganic & medicinal chemistry
Published: July 02, 2013
Showing 1-3 of 3
Last Updated: 09/26/2026